448 related articles for article (PubMed ID: 18803994)
1. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
[TBL] [Abstract][Full Text] [Related]
2. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
Walthour A; Seymour L; Tackett R; Perri M
Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
[TBL] [Abstract][Full Text] [Related]
3. Medicaid prescription cost containment and schizophrenia: a retrospective examination.
Farley JF
Med Care; 2010 May; 48(5):440-7. PubMed ID: 20351586
[TBL] [Abstract][Full Text] [Related]
4. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
5. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
6. Effects of antipsychotic medication on psychiatric service utilization and cost.
Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
Sankaranarayanan J; Puumala SE
Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
9. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.
Law MR; Ross-Degnan D; Soumerai SB
Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014
[TBL] [Abstract][Full Text] [Related]
10. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population.
Delate T; Mager DE; Sheth J; Motheral BR
Am J Manag Care; 2005 Jan; 11(1):29-36. PubMed ID: 15697098
[TBL] [Abstract][Full Text] [Related]
11. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
[TBL] [Abstract][Full Text] [Related]
12. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
14. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.
Nightengale BS; Crumly JM; Liao J; Lawrence BJ; Jacobs EW
Psychopharmacol Bull; 1998; 34(3):373-82. PubMed ID: 9803771
[TBL] [Abstract][Full Text] [Related]
15. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
[TBL] [Abstract][Full Text] [Related]
16. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
[TBL] [Abstract][Full Text] [Related]
17. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
[TBL] [Abstract][Full Text] [Related]
18. Medicaid's prior authorization program and access to atypical antipsychotic medications.
Polinski JM; Wang PS; Fischer MA
Health Aff (Millwood); 2007; 26(3):750-60. PubMed ID: 17485754
[TBL] [Abstract][Full Text] [Related]
19. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
20. The implementation of managed behavioral healthcare in Colorado and the effects on older Medicaid beneficiaries.
Kaskie B; Wallace N; Kang S; Bloom J
J Ment Health Policy Econ; 2006 Mar; 9(1):15-24. PubMed ID: 16733268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
